Randomized Trial Comparing Early "Trigger" Versus Delayed "Trigger" Timing in Cycles of Controlled Ovarian Stimulation.
NCT05498350
Recruiting
This randomized trial will compare the efficacy of two different times of administration of medications for final oocyte maturation, commonly called a "trigger", in cycles of controlled ovarian stimulation (COS) for cycles in which all embryos will be cryopreserved ("freeze-all cycles").
Gender:
FEMALE
Ages:
Between 18 years and 34 years
Trial Updated:
08/10/2022
Locations: Fertility center of Las Vegas, Las Vegas, Nevada
Conditions: Infertility, Female
Register for Updates
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357
Recruiting
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2022
Locations: Eye Research Foundation Inc., Newport Beach, California +8 locations
Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Register for Updates
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
NCT02285959
Recruiting
The high-grade malignant brain tumor glioblastoma multiforme (GBM) comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for GBM. Initial therapy consists of surgical resection, external beam radiation or both. Currently, all patients experience a recurrence after this first-line therapy, so improvements in both first-line and salvage therapy are critical to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2022
Locations: Not set, Philadelphia, Pennsylvania
Conditions: Glioblastoma Multiforme
Register for Updates
Assessment for Implementation Methods in Sepsis
NCT05491941
Recruiting
Since the introduction of sepsis bundles, there have been multiple published trials that have demonstrated a consistent, strong association between implementation of sepsis "bundles" (3-hour bundle) and improved survival. The current proposal is a Hybrid 2, pragmatic, cluster randomized clinical effectiveness/implementation trial evaluating mortality and respiratory failure-based outcomes, in patients admitted to the emergency department with sepsis, comparing the effectiveness of implementation... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2022
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Sepsis Severe, Septic Shock
Register for Updates
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
NCT04985032
Recruiting
This is a multi-institutional, prospective, observational registry investigating the safety and efficacy of Accelerated Partial Breast Irradiation (APBI) using a Stereotactic Body Radiation Therapy (SBRT) delivery technique that incorporates real-time image guidance, noncoplanar fields, and respiratory tracking. The study will accrue 200 patients who will be treated to a dose of 30 Gy over the course of 5 fractions. These subjects will then have a follow up time of 5 years
Gender:
FEMALE
Ages:
Between 50 years and 100 years
Trial Updated:
08/03/2022
Locations: CyberKnife Center of South Florida in Stuart, Stuart, Florida +1 locations
Conditions: Ductal Carcinoma in Situ, Invasive Ductal Carcinoma of Female Breast
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama +68 locations
Conditions: Breast Cancer
Register for Updates
Child Healthcare at MATER - Pediatric Study
NCT05488379
Recruiting
The objective of this project is to implement and evaluate a group model of well child care for mothers in treatment for opioid use disorder and their children that addresses the specific health needs and concerns of opioid-exposed infants, is trauma informed, and is embedded within a maternal opioid use disorder treatment program. 108 mother-infant dyads will be randomized 1:1 to group well child care or individual well child care, and followed over an 18 month period. Qualitative and quantitat... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Opioid Use Disorder
Register for Updates
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
NCT04270591
Recruiting
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/28/2022
Locations: Norton Cancer Institute, Louisville, Kentucky +43 locations
Conditions: C-Met Exon 14 Mutation
Register for Updates
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
NCT05430009
Recruiting
Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/27/2022
Locations: Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan
Conditions: Liver Metastases, Non-small Cell Lung Cancer
Register for Updates
USCRI READY4Life Program
NCT05476185
Recruiting
The U.S. Committee for Refugees and Immigrants (USCRI) has developed the Relationships, Education, Advancement, and Development for Youth for Life (READY4Life) Program. This is a 16-hour program for immigrants/refugees, ages 14 to 24. The program is designed to help young immigrants and refugees prepare for a successful life in the United States. The program is taught by USCRI program staff and is being implemented at eight sites across the U.S.: Cleveland, Ohio; Colchester, Vermont; Des Moines,... Read More
Gender:
ALL
Ages:
Between 14 years and 24 years
Trial Updated:
07/27/2022
Locations: United States Committe on Refugees and Immigrants, Washington, District of Columbia +8 locations
Conditions: Communication, Problem Solving, Social Relationships, Economic Stability
Register for Updates
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
NCT03326336
Recruiting
The objective of this study is to evaluate the safety and tolerability of escalating doses of a gene therapy called GS030-DP (injected study treatment) administered via a single intravitreal injection and repeated light stimulation using a medical device called GS030-MD (stimulating glasses) in subjects with documented diagnosis of non-syndromic Retinitis Pigmentosa
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/25/2022
Locations: UPMC Eye Center, Pittsburgh, Pennsylvania +2 locations
Conditions: Non-syndromic Retinitis Pigmentosa
Register for Updates
A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients
NCT04699695
Recruiting
This is a prospective, multicenter, sample collection study using DermTech's non-invasive skin collection kits to evaluate genomic biomarkers and microbiome information from pediatric and adult subjects with atopic dermatitis(AD). Samples collected will be analyzed to detect gene signatures and microbiome populations associated with AD and sub-populations of AD.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
07/25/2022
Locations: Orit Markowitz, New York, New York +1 locations
Conditions: Atopic Dermatitis
Register for Updates